Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

Glenmark Pharmaceuticals Limited (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel®1 Tablets, 200 mg and 400 mg of Eisai, Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on May 16, 2016.

Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, "We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel® Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients."

According to IQVIA™ sales data for the 12 month period ending April 2021, the Banzel® Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million*.

Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.592.6 as compared to the previous close of Rs. 607.1. The total number of shares traded during the day was 203806 in over 6129 trades.

The stock hit an intraday high of Rs. 600.75 and intraday low of 578.65. The net turnover during the day was Rs. 120471819.

Source : Equity Bulls

Keywords